INCR News and Press, Intercure Ltd. From 03/01/22

The partnership will focus on the new CBD wellness market in Israel Israeli Minister of Health announced yesterday that CBD will be removed from the Dangerous Drugs Act Altman Health is the market leader in health and wellness with distribution across the country N...

InterCure provided strong preliminary results for Q4'21. The Israeli company has a major catalyst in the future approval of recreational cannabis in their home country. The stock is cheap trading at less than 3x '22 sales targets with major catalysts ahead. For further detai...

Israeli-based cannabis producer Inter C ure Ltd . (NASDAQ: INCR) also known as Canndoc is buying medical cannabis company Cann Pharmaceutical Ltd. also known as Better in a deal valued at $35 million. It is expected to close at the beginning of the third quarter of 2022. ...

InterCure (NASDAQ:INCR) signed a definitive agreement with Cann Pharmaceutical, a pioneering Israeli medical cannabis multi-national operator known as "Better". Under agreement terms, InterCure will acquire 100% of Better’s shares, which includes Better's unique strains, cultivati...

Marking the First Major Consolidation in Pharmaceutical Grade Medical Cannabis Market Acquisition is Expected to be Accretive Strengthen InterCure’s Position as the Largest Cannabis Company Outside of North America NEW YORK and TORONT...

Gainers: BioDelivery Sciences International (NASDAQ:BDSI) +52%. Knightscope (NASDAQ:KSCP) +31%. Ebang International (NASDAQ:EBON) +22%. Cornerstone Building Brands (NYSE:CNR) +22%. Kelly Services (NASDAQ:KELYA) +18%. NRx Pharmaceuticals (NASDAQ:NRXP) +17%. Cadiz (NASDAQ:CDZI) +...

Israeli-based InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) announced its preliminary financial results for the fourth quarter of 2021. All amounts are expressed in Canadian dollars ($) or New Israeli Shekels (NIS). Revenue is estimated to be over $31 million, three times greater t...

InterCure (NASDAQ:INCR) estimates Q4 prelim revenue to be over C$31M, three times greater than the year ago quarter and 24% higher from previous quarter; FY21 revenue of C$87M (+250% Y/Y). It is expected to see eighth consecutive quarter of high double-digit growth representing an annualized ...

Estimated revenue reaches over CAD$31 million (a record NIS 77 million) Anticipates continued increases in adjusted operating profit and EBITDA Revenue growth expected to continue throughout 2022 TORONTO and HERZLIYA, Israel, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Int...

Intercure (NASDAQ:INCR) expands into Europe through a partnership with iconic cannabis brand Cookies. The parties entered into a multi-year agreement under which InterCure expects to establish Cookies stores and medical cannabis pharmacies in Austria and the Unit...